TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10867681

Group type: EXPERIMENTAL
Intervention: Causes of migration and reasons for staying overnight as risk factors for malaria.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of prevention as a risk factor affecting prevalence of malaria.
Number of subjects: 0
Study: 7612555

Group type: EXPERIMENTAL
Intervention: Intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Simple excision without mitomycin C
Number of subjects: 54
Study: 1369849

Group type: EXPERIMENTAL
Intervention: Obturator neurectomy
Number of subjects: 34
Study: 25237

Group type: EXPERIMENTAL
Intervention: 10 mg etilefrin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 mg dihydroergotamine
Number of subjects: 60
Study: 31429006

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg once/day) in addition to conventional therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 108
Study: 31122188

Group type: EXPERIMENTAL
Intervention: CGRP mAbs (any preventive)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29479923

Group type: EXPERIMENTAL
Intervention: Protective pressure ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 60
Study: 25284704

Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg oral dose) with STN‐DBS ON
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg oral dose) with STN‐DBS OFF
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo with STN‐DBS ON
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo with STN‐DBS OFF
Number of subjects: 16
Study: 22328460

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral pain management program (6 sessions for children, 1 meeting for parents)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 29
Study: 21204682

Group type: EXPERIMENTAL
Intervention: Biking alone with iPod
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Biking alone with a friend
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Walking alone with iPod
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Walking alone with a friend
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control conditions (biking or walking alone)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Exercising outdoors
Number of subjects: 229
Study: 18468572

Group type: EXPERIMENTAL
Intervention: Newer procedure (rectus fascia sling)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Older procedure (mesh sling)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: General perception of newer procedures
Number of subjects: 48
Study: 16902083

Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hospital clinic-based chemotherapy
Number of subjects: 38
Study: 14712894

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 0
Study: 11130089

Group type: EXPERIMENTAL
Intervention: Misoprostol, 50 micrograms intravaginally every 6 hours for a maximum of 24 hours
Number of subjects: 210

Group type: COMPARATOR
Intervention: Dinoproston, 0.5 mg intracervically every 12 hours for a maximum of 24 hours
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 210

Group type: COMPARATOR
Intervention: Dinoproston
Number of subjects: 210
Study: 9387966

Group type: EXPERIMENTAL
Intervention: Manoeuvre 1 (fast inspiration without an end‐inspiratory pause)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Manoeuvre 2 (slow inspiration with an end‐expiratory pause of approximately 5 s)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maximal expiratory flows at the same lung volume with manoeuvre 1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Maximal expiratory flows at the same lung volume with manoeuvre 2
Number of subjects: 11
Study: 8339645

Group type: EXPERIMENTAL
Intervention: Magnesium infusion (6 g MgSO4 i.v. over 16 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 3732368

Group type: EXPERIMENTAL
Intervention: Twice-daily administration of beclomethasone dipropionate aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four-times daily administration of beclomethasone dipropionate aerosol
Number of subjects: 0
Study: 29985226

Group type: COMPARATOR
Intervention: Plyometric group (PG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Strength group (SG)
Number of subjects: 23
Study: 27073236

Group type: EXPERIMENTAL
Intervention: Irregular shape of hematoma
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Heterogeneous density of hematoma
Number of subjects: 2066
Study: 24881023

Group type: EXPERIMENTAL
Intervention: Web-based follow-up
Number of subjects: 229

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 229
Study: 22326841

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 60 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 20230725

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 g/kg)
Number of subjects: 30
Study: 18616516

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) energy delivery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) regimen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Health-related quality of life scores
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oesophageal acid exposure (OAE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Severe complications
Number of subjects: 36
Study: 15710761

Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents (SR)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents (MR)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 536
Study: 12428223

Group type: EXPERIMENTAL
Intervention: Anakinra (30, 75, or 150 mg) once daily
Number of subjects: 309
Study: 10327336

Group type: EXPERIMENTAL
Intervention: EPI T1W sequence
Number of subjects: 70

Group type: COMPARATOR
Intervention: TSE T1W sequence
Number of subjects: 70

Group type: COMPARATOR
Intervention: UTSE T2W sequence
Number of subjects: 70

Group type: COMPARATOR
Intervention: TSE T1W - UTSE T2W
Number of subjects: 70

Group type: COMPARATOR
Intervention: EPI T1W - UTSE T2W
Number of subjects: 70
Study: 8932547

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meloxicam 30 mg
Number of subjects: 0
Study: 1616391

Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 86
Study: 6730996

Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Barbital (Diemal)
Number of subjects: 72
Study: 31122962

Group type: EXPERIMENTAL
Intervention: Pilot or feasibility trials evaluating feasibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot or feasibility trials
Number of subjects: 0
Study: 28719227

Group type: EXPERIMENTAL
Intervention: Simvastatin (20-40 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27467969

Group type: EXPERIMENTAL
Intervention: Discharge BNP
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Admission BNP
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Percentage BNP reduction
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Combination of discharge BNP ≤319pg/mL and percentage BNP reduction ≥7.71%
Number of subjects: 433
Study: 25200142

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Clopidogrel with Aspirin followed by Clopidogrel
Number of subjects: 5500
Study: 22094110

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 187
Study: 20654757

Group type: EXPERIMENTAL
Intervention: Pharmacy-administered DMPA-SC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinic-administered DMPA-SC
Number of subjects: 50
Study: 18316422

Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (CBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Stress management training (CBT)
Number of subjects: 108
Study: 15834056

Group type: EXPERIMENTAL
Intervention: Physiotherapy with exercises aiming at strengthening the stabilisers and decompressors of the shoulder
Number of subjects: 90

Group type: COMPARATOR
Intervention: Arthroscopic subacromial decompression
Number of subjects: 90
Study: 12434893

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (2.5 mmol/L serum Mg2+)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 22
Study: 10651230

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride
Number of subjects: 40
Study: 8936959

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human growth hormone (GH) 15 U/m2/week for 1 year (Groups (I)b, (II)a, (III)b)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: GH 30 U/m2/week for 1 year (Group (I)a)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: GH therapy (both doses) for 1 year
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: GH therapy (Group (III))
Number of subjects: 77
Study: 1656741

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, followed by 250 mg/day on days 2-5)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Cephalexin (500 mg twice daily for 10 days)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 361
Study: 6785476

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31734538

Group type: EXPERIMENTAL
Intervention: eVLU (internet-based education about VLU nursing care) for 6 weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 468
Study: 28463716

Group type: EXPERIMENTAL
Intervention: TAU + ICBT (n=33)
Number of subjects: 69

Group type: COMPARATOR
Intervention: TAU (n=36)
Number of subjects: 69
Study: 27112532

Group type: EXPERIMENTAL
Intervention: SBI-087 (IV administration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SBI-087 (SC administration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SBI-087 (both IV and SC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SBI-087 (with pre/posttreatment regimen)
Number of subjects: 90
Study: 24332446

Group type: COMPARATOR
Intervention: High contrast PR-VEP
Number of subjects: 75

Group type: COMPARATOR
Intervention: P100-N145 amplitude in high contrast PR-VEP
Number of subjects: 75

Group type: COMPARATOR
Intervention: M-VEP (P1-N2 amplitudes)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low contrast PR-VEP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low contrast and motion-onset stimuli
Number of subjects: 75
Study: 22036871

Group type: EXPERIMENTAL
Intervention: Exercise training (3 training sessions per week for 10 consecutive weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 54
Study: 20092407

Group type: EXPERIMENTAL
Intervention: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Primary vaccination or revaccination with PN23
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Revaccination with PN23
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Serotype 3 antibody levels
Number of subjects: 1008
Study: 17906203

Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy (CT)
Number of subjects: 785

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 785
Study: 16307705

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% (Lumigan) eye drops
Number of subjects: 83

Group type: COMPARATOR
Intervention: Filtration surgery (FS)
Number of subjects: 83
Study: 11895063

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor and beta-blocker therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left-ventricular end-diastolic volume (LVEDV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma b-type natriuretic peptide (BNP)
Number of subjects: 0
Study: 9798584

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg or 80 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gemeprost 1 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gemeprost
Number of subjects: 66
Study: 7865646

Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg 5-ASA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multiple oral dose of 2400 mg/day for 56 days of 5-ASA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study: 2645553

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% once-daily treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% twice-daily treatment
Number of subjects: 71
Study: 31343520

Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA) (18.9 ± 1.9 kcal·kg FFM·d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal energy availability (NEA) (52.9 ± 5.0 kcal·kg FFM·d)
Number of subjects: 7
Study: 29534902

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 684

Group type: COMPARATOR
Intervention: No postmastectomy radiation therapy (no-PMRT)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with no taxane
Number of subjects: 684

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with no taxane (no-PMRT)
Number of subjects: 684
Study: 28222779

Group type: EXPERIMENTAL
Intervention: Retrograde perfusion with endoaortic clamp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transthoracic clamp
Number of subjects: 0
Study: 26153884

Group type: EXPERIMENTAL
Intervention: Active video games and encouragement to play
Number of subjects: 270

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 270
Study: 23458257

Group type: EXPERIMENTAL
Intervention: Resistance exercise for 8 weeks
Number of subjects: 17
Study: 20672727

Group type: EXPERIMENTAL
Intervention: All Bond 3 (AB3) applied with various procedures (A, B, C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All Bond Self‐Etch (ABSE) applied with various procedures (A, B, C)
Number of subjects: 0
Study: 18387444

Group type: EXPERIMENTAL
Intervention: VASP-guided group (additional bolus clopidogrel to decrease VASP index below 50%)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study: 16631617

Group type: EXPERIMENTAL
Intervention: Dark soy sauce (DSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15645932

Group type: EXPERIMENTAL
Intervention: meridol toothbrush with tapered filaments
Number of subjects: 87

Group type: COMPARATOR
Intervention: ADA reference toothbrush
Number of subjects: 87
Study: 10910026

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) performed on 5 consecutive days using an adsorber against immunoglobulins (Ig Therasorb, Baxter) with substitution of 0.5 g/kg of polyclonal immunoglobulin after the final session
Number of subjects: 9
Study: 8852866

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 1353386

Group type: EXPERIMENTAL
Intervention: Prazosin 3 mg b.d. for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 16
Study: 6584389

Group type: EXPERIMENTAL
Intervention: 3 X 100 mg oxyphenbutazone daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 31403350

Group type: EXPERIMENTAL
Intervention: Hydrosurgery
Number of subjects: 93

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 93
Study: 31551204

Group type: EXPERIMENTAL
Intervention: Ulinastatin and thymosin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 68
Study: 30011395

Group type: EXPERIMENTAL
Intervention: Unfortified human milk (UHM)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Fortified human milk (FHM)
Number of subjects: 281
Study: 26754447

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 50
Study: 24495849

Group type: EXPERIMENTAL
Intervention: Emotional context (emotional pictures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral context (neutral pictures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zero context (blank screens)
Number of subjects: 0
Study: 22764337

Group type: EXPERIMENTAL
Intervention: Perifacet injection into the lumbar multifidus muscle with methylprednisolone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Back education and gym ball exercise for 10 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Back education and standard physiotherapy for 10 weeks
Number of subjects: 63
Study: 20142346

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/mL, 20 mL given every third hour for 72 hours postoperatively.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine group.
Number of subjects: 40
Study: 16943848

Group type: EXPERIMENTAL
Intervention: Traditional baguette
Number of subjects: 9

Group type: COMPARATOR
Intervention: Classic baguette
Number of subjects: 9
Study: 15827103

Group type: EXPERIMENTAL
Intervention: Calcium (1 g/d)
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471
Study: 12479545

Group type: EXPERIMENTAL
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, approximately 8.5 mg/kg/day) given simultaneously for three days
Number of subjects: 204

Group type: COMPARATOR
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially administered)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, simultaneously)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Group A (simultaneous)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Group B (sequential)
Number of subjects: 204
Study: 10531816

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention conducted in the clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 9497660

Group type: EXPERIMENTAL
Intervention: Acuhealth treatment (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acuhealth and occlusal splint therapy (group C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (group D)
Number of subjects: 100
Study: 2104736

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nitroglycerin 0.8 mg spray
Number of subjects: 15
Study: 281221

Group type: EXPERIMENTAL
Intervention: DTIC plus C.parvum
Number of subjects: 69

Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 5FU plus C.parvum
Number of subjects: 69

Group type: COMPARATOR
Intervention: 5FU
Number of subjects: 69
Study: 30453910

Group type: EXPERIMENTAL
Intervention: Ruxolitinib and best available treatment (BAT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Best available treatment (BAT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ruxolitinib and BAT
Number of subjects: 160

Group type: COMPARATOR
Intervention: BAT
Number of subjects: 160
Study: 28369188

Group type: EXPERIMENTAL
Intervention: Postoperative self administration of intra‐venous analgesia by patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principal stratification and mediation analysis
Number of subjects: 0
Study: 26195001

Group type: EXPERIMENTAL
Intervention: S. platensis supplementation and standard care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard care and local balanced diet without S. platensis
Number of subjects: 320
Study: 23824463

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT, n = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control Group (CG, n = 12)
Number of subjects: 34
Study: 21161463

Group type: COMPARATOR
Intervention: OTW (over-the-wire balloon technique)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PC (perfusion catheter)
Number of subjects: 34
Study: 18498013

Group type: EXPERIMENTAL
Intervention: Close Monitoring (CM)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 223
Study: 16192577

Group type: EXPERIMENTAL
Intervention: Bec2 (2.5 mg)/BCG vaccine
Number of subjects: 515

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Bec2/BCG vaccine (among vaccinated patients)
Number of subjects: 515